Modalis Therapeutics Corporation (JP:4883) has released an update.
Modalis Therapeutics Corporation is set to present their cutting-edge CRISPR-GNDM® technology and share data supporting the development of their lead program MDL-101 for LAMA2-Congenital Muscular Dystrophy at the 5th Annual Genome Editing Therapeutics Summit. The company’s innovative epigenome editing approach offers potential for a one-time, durable treatment for this rare genetic disease. Modalis Therapeutics, a leader in the field of genome editing therapeutics, continues to advance its research with a focus on non-hepatic disorders.
For further insights into JP:4883 stock, check out TipRanks’ Stock Analysis page.